3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
5
Unknown
4
Terminated
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Vomiting
1
Recurrence
1
Pancreatic Neoplasms
1
Nausea
1
Multiple Myeloma
1
Medulloblastoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Large Granular Lymphocytic
1
Ependymoma
1
Interventions
Cyclophosphamide
21
venetoclax
18
pembrolizumab
16
Dexamethasone
16
fludarabine
14
Cytarabine
13
Gemcitabine
9
pomalidomide
8
Rituximab
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
Immunotherapy, Adoptive
7
selinexor
6
Paclitaxel
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Oxaliplatin
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
Thalidomide
×
Clear all
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled